
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is currently facing challenges due to geopolitical pressures and macroeconomic headwinds, which have led to lower orders and revenue. However, the company's transformation plan is underway, and management remains committed to achieving a high single-digit adjusted EBITDA margin and a double-digit margin in the long-term, presenting potential upside for investors. While the company's earnings and order volume have been impacted, they continue to innovate with their CyberKnife technology, providing precise and efficient treatment options for cancer patients.
Bears say
Accuray is currently facing several challenges that have led us to have a negative outlook on the stock. Firstly, the company's recent transformation plan has not yielded the expected results, with declining revenue and missed earnings expectations. Additionally, geopolitical uncertainty in the Middle East has affected the company's ability to make sales and fulfill orders, leading to a lack of visibility on a potential turnaround. In light of these factors, we have downgraded our rating from Buy to Neutral and removed our price target.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares